



(51) International Patent Classification:

A61P 35/00 (2006.01) C07F 9/6561 (2006.01)

(21) International Application Number:

PCT/US2022/078822

(22) International Filing Date:

27 October 2022 (27.10.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:


63/273,454 29 October 2021 (29.10.2021) US

(71) Applicant: GILEAD SCIENCES, INC. [US/US]; 333
Lakeside Drive, Foster City, California 94404 (US).(72) Inventors: BARTLETT, Mark J.; c/o Gilead Sciences,
Inc., 333 Lakeside Drive, Foster City, California 94404
(US). CHIN, Gregory F.; c/o Gilead Sciences, Inc.,
333 Lakeside Drive, Foster City, California 94404 (US).
CLARKE, Michael O.; c/o Gilead Sciences, Inc., 333
Lakeside Drive, Foster City, California 94404 (US). COS-
MAN, Jennifer L.; c/o Gilead Sciences, Inc., 333 Lakeside
Drive, Foster City, California 94404 (US). ENSAN, Deeba;
c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster
City, California 94404 (US). GOYAL, Bindu; c/o Gilead

Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US). HO, Stephen; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US). MACKMAN, Richard L.; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US). MISH, Michael R.; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US). SIEGEL, Dustin S.; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US). TAMSHERN, Kyle C.; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US). YANG, Hai; c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404 (US).

(74) Agent: POLSTER, Philip B. et al.; Gilead Sciences, Inc.,
333 Lakeside Drive, Foster City, California 94404 (US).(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG,
NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,
RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

(54) Title: CD73 COMPOUNDS



(57) Abstract: Provided herein is A compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein the various substituents are described herein.




FIG. 1

[Continued on next page]

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*